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Type 2 diabetes is a disease plaguing the American population, bringing along with it a 
number of complications.  With millions of dollars spent annually to care for diabetic patients 
and the complications of diabetes, much remains to be known regarding newer medications and 
the effects of those complications.  Two sodium glucose co-transporter 2 inhibitors, canagliflozin 
and empagliflozin, and one glucagon-like peptide-1 receptor agonist, liraglutide, have proven 
cardiovascular benefit; however, their use in combination with metformin has not been well 
studied when compared to metformin and sulfonylurea therapy. While there are studies 
underway evaluating such outcomes, a critical review of current literature has revealed a lack of 
research to aid in the decision-making process of type 2 diabetes treatment.  
PREVALENCE 
Type 2 diabetes mellitus is a disease affecting more than 23.1 million Americans, 
accounting for approximately 7.2% of the population.1 It is estimated that only approximately 5% 
of this population has Type 1 diabetes mellitus, leaving about 21.9 million Americans who are 
living with Type 2 diabetes and the complications thereof.  It is estimated that 33.9% of all US 
adults are living with prediabetes, based on fasting blood glucose levels and/or A1c levels.1  
While it affects men and women equally, diabetes is a discriminatory disease that favors 
African Americans and Hispanics more than the non-Hispanic white population.  It has a higher 
incidence in counties in the southern and Appalachian regions of the country, and its incidence 
is twice as high in those with education levels less than high school.1 In the United States alone, 
diabetes accounted for $245 billion in medical expenditures in diagnosed patients.1 This amount 
does not account for diagnosis, treatment, and complications of patients living with undiagnosed 
diabetes.   
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PATHOPHYSIOLOGY 
Type 2 diabetes mellitus is characterized by two main pathophysiologic processes that 
jointly contribute to the progression of the disease.  Over time, it is known that  cell function 
decreases in the pancreas leading to impaired insulin secretion and a decrease in overall response 
to glucose concentrations.2 In addition, major organs within the body develop a resistance to 
insulin secreted by the pancreas. The human body then lacks response to what would typically 
be a normal concentration of insulin secreted to control rising glucose concentrations.2 
Researchers, scientists, and medical experts know that there is a genetic component that 
contributes to the predisposition for diabetes mellitus.  It is also known that environmental 
factors and lifestyle choices contribute to declining  cell function.  Increased caloric intake, poor 
dietary choices, and decreased activity levels contribute to the development of excess adipose 
tissue, and thus, the development of insulin resistance and decreased  cell function.2 These facts 
guide clinician counseling of diet and exercise as an essential adjunct to the mainstay of therapy 
for diabetic patients.  
STANDARDS OF CARE & TREATMENT 
The current standard of care in the initial management of type 2 diabetes is lifestyle 
interventions and Metformin. Metformin is titrated up to a maximum daily dose of 2000mg, as 
the patient can tolerate.3 Metformin as monotherapy has been shown to reduce A1c levels by 
approximately 1%.3-4 According to current literature, an important consideration in the next step 
in glycemic control in patients with atherosclerotic cardiovascular disease is the initiation of a 
drug with known cardiovascular benefit in addition to Metformin.  
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Currently, three pharmaceutical agents have proven cardiovascular benefit (canagliflozin, 
empagliflozin, liraglutide), two of which have been FDA approved for such benefit (empagliflozin 
and liraglutide).3-4 These drugs, however, have an associated financial barrier as they are 
significantly more expensive than other oral agents commonly used (i.e., sulfonylureas and 
thiazolidinediones).4 It is known  there is an association of increased mortality with decreased 
education status and financial wealth.5  Providers don’t know, however, whether or not the use 
of more affordable options (simply due to financial and socioeconomic factors) in combination 
with metformin is placing patients at higher risk of significant cardiovascular events than using 
newer agents, while more expensive, with proven cardiovascular benefits.  
INCRETIN THERAPIES 
In the management of type 2 diabetes, Incretin therapy encompasses two types of agents, 
GLP-1 agonists and DPP-4 Inhibitors. Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) 
mimic the action of the glucagon-like peptide through binding to a surface hormone on  cells in 
the pancreas.6  This increases  cell sensitivity to glucose, protects these cells from apoptosis, 
and triggers proliferation that increases  cell mass. These agents also suppress  cell secretion 
of glucagon, reducing glucose production within the liver and delaying gastric emptying. GLP-1 
agonists also act on the hypothalamus to stimulate early satiety.6  
Dipeptidyl peptidase 4 inhibitors (DPP-4 Inhibitors) act through preventing the enzymatic 
breakdown of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). These agents also 





Having only been approved for use for a little more than a decade, there is much to be 
discovered regarding this new class of antihyperglycemic agents and its effects on different organ 
systems. The TECOS trial sought to assess the long-term cardiovascular safety of adding 
Sitagliptin, the longest approved DPP-4 inhibitor, to usual care in patients with type 2 diabetes 
and cardiovascular disease.  In this randomized, double-blind study, patients were assigned to 
add either sitagliptin or a placebo to their existing treatment plan.  These patients were followed 
and cardiovascular outcomes were monitored, to include cardiovascular death, nonfatal MI or 
stroke, or hospitalization for unstable angina.  Patients’ A1c was measured periodically 
throughout the study and researchers found that at 4 months, the average A1c was lower in the 
sitagliptin group than the placebo group.  In addition, sitagliptin group participants received 
fewer antihyperglycemic agents than placebo and those in the sitagliptin group were less likely 
to start insulin therapy.7   
Researchers found there was no significant difference in the primary cardiovascular 
outcome and in the secondary cardiovascular outcome between the sitagliptin group and 
placebo. In addition, there was no significant difference in rate of hospitalization for heart failure, 
as is a concern for DPP-4 inhibitors.7  This trial found that adding sitagliptin to a patient’s medical 
regimen did not affect the rates of cardiovascular events.  While this is true, the results cannot 
be extrapolated to include patients taking DPP-4 inhibitors for a longer period of time or to 
patients with more complicated medical presentations.7 The TECOS trial, while critical in the 
evaluation of cardiovascular safety, failed to clarify the question of cardiovascular outcomes 
associated with DPP-4 inhibitors.  
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A meta-analysis of clinical trials performed by Wu et al. aimed to evaluate the 
cardiovascular safety and efficacy of DPP-4 inhibitors. In this study, prospective randomized 
controlled trials were obtained and evaluated for all-cause mortality, cardiovascular mortality, 
acute coronary syndrome, stroke, and heart failure outcomes.  Some of the trials were placebo-
controlled, while others used an active comparator. Multiple DPP-4 inhibitors were compared 
against metformin, sulfonylureas, and thiazolidinediones.    
When compared to placebo and active comparators, there was no significant difference 
in all-cause mortality or in cardiovascular mortality. In comparison to active comparators, DPP-4 
inhibitors showed a statistically significant reduction in acute coronary syndrome. There was a 
significant reduction in stroke when DPP-4 inhibitors were compared to active comparators. 
However, there was a significant increase in heart failure hospitalizations with DPP-4 inhibitors.  
This increase was significant only when compared to placebo groups but was not significant when 
compared to active comparators.8 
In the same study, researchers discussed the effects of DPP-4 inhibitors that would 
suggest cardiovascular benefit.  In addition to being weight neutral, or potentially contributing to 
weight loss, DPP-4 inhibitors decrease blood pressure, improve postprandial lipemia, reduce 
inflammatory markers, diminish oxidative stress, and improve endothelial function.8 In addition, 
DPP-4 inhibitors improve cardiac contractility in diabetic patients.  There have been no direct 
explanations provided for the increase in heart failure hospitalizations.  While there has been a 
neutral effect found on all-cause and cardiovascular mortality, the implications of an increase in 
heart failure hospitalizations requires further evaluation.  
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Few studies have directly discussed cardiovascular outcomes of DPP-4 inhibitors.  Jose 
and Inzuchhi review multiple DPP-4 inhibitors and discuss the cardiovascular effects of each.  
Sitagliptin does not appear to pose additional cardiovascular risk to patients.9  In a study 
evaluating saxagliptin, researchers found no cardiovascular harm and a potential for a decrease 
in cardiovascular events (measured as death, myocardial infarction, stroke, revascularization 
procedures, and ischemia).9  Studies evaluating alogliptin found a numerically lower risk of 
cardiovascular outcomes, although not statistically significant.  One study that evaluated DPP-4 
inhibitors showed a 31% reduction in cardiovascular events, a rate that hasn’t been shown by 
many other studies prompting concern and the need for additional research.   
GLP-1 AGONISTS 
The LEADER trial was an integral trial in the treatment of type 2 diabetes and associated 
cardiovascular outcomes.  In this multinational study, patients without a history of cardiovascular 
disease (CVD), but high risk, were evaluated alongside patients with known CVD to determine 
the effect of treatment with liraglutide compared to placebo on cardiovascular outcomes.10 
Researchers defined cardiovascular events as cardiovascular death, nonfatal MI, or nonfatal 
stroke in patients with type 2 diabetes. LEADER was unique in that it targeted high risk patients, 
either with or without a history of cardiovascular disease and comorbid cardiac related 
conditions.  
Liraglutide is known to decrease A1c 1.0-1.5%. While its mechanism on cardiovascular risk 
requires further research, multiple mechanisms have been identified that could contribute to 
lowering the risk for type 2 diabetic patients. GLP-1 agonists account for significant weight loss 
and a decrease in systolic blood pressure.  It is also hypothesized that there may be a direct effect 
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on cardiac myocytes and the endothelium.  Studies have shown there is no negative impact on 
lipid profiles and cardiovascular risk and some results even favor an improvement in triglycerides 
and free fatty acids.  Other studies have shown a decrease in BNP and PAI-1, two very important 
cardiac health markers.10  
The LEADER trial found that fewer patients in the liraglutide group died from 
cardiovascular events, experienced nonfatal MIs or nonfatal strokes than those in the placebo 
group. In addition, the all-cause mortality was lower in the liraglutide group than the placebo 
group. The rates of nonfatal MI or stroke were lower in the liraglutide group when compared to 
placebo. This trial also showed a greater increase in weight loss and a greater decrease in systolic 
and diastolic blood pressure in the liraglutide recipients when compared to placebo, while 
experiencing a mild increase in heart rate.11 The incidence of renal or retinal microvascular events 
was lower in the liraglutide group when compared to placebo, although the incidence of 
retinopathy was not significantly higher in the liraglutide group. It is important to outline the 
potential risks associated with the use of liraglutide, including pancreatitis, pancreatic cancer, 
and thyroid T-cell tumors. More research is needed to evaluate these potential complications of 
treatment.  
Pfeffer et al. evaluated the effects of adding lixisenatide to a medication regimen for 
patients who recently experienced an acute coronary event.  This study included patients who 
had experienced a myocardial infarction or had been hospitalized for unstable angina within the 
preceding 180 days.  Researchers evaluated patients for cardiovascular death, MI, stroke, or 
hospitalization for unstable angina as primary outcomes. After randomization and addition of 
lixisenatide, researchers found that this drug was noninferior to placebo, but also did not find 
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superiority.  There were no significant differences in heart failure hospitalizations or death rates, 
and there was no difference in serious adverse events, including pancreatitis, pancreatic cancer, 
or allergic reactions.  Pfeffer et al. concluded there was no significant change in cardiovascular 
events with the addition of lixisenatide.12 
A study by Nauck outlines a few disadvantages and advantages of incretin therapies, to 
include GLP-1 agonists and DPP-4 inhibitors. Important components that warrant further 
investigation include a potential for an increased risk of pancreatitis and neoplastic lesions that 
could promote the development of pancreatic cancer.13 Previous studies have also raised 
concern of thyroid C-cell proliferation that could lead to thyroid cancers.  Simply put, these 
findings certainly warrant further investigation and research. Despite the potential negative 
implications of using incretin therapies, there have been studies showing an association between 
use and a reduction in body weight.13 GLP-1 agonists have also been shown to improve 
endothelial function, dilate blood vessels, and improve natriuresis and fluid excretion, thus 
reducing blood pressure.  Due to a stimulation of glucose and oxygen intake into the myocardium, 
researchers have found a potential increase in cardiac output.13  
TRADITIONAL THERAPY 
Many healthcare providers prefer to use older and more traditional methods of oral 
combination therapies in the treatment of type 2 diabetes. These methods include metformin 
and sulfonylurea combination therapy. While certainly more affordable, these medications carry 
risks that should be carefully evaluated by prescribers.  
A study by Roumie et al. evaluated the time to acute MI, stroke, or death in Metformin 
patients adding either insulin or a sulfonylurea.  At the time of addition of the second medication, 
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patients had been stabilized on metformin for several months.  Compared against patients who 
added sulfonylureas, the addition of insulin was associated with an increased risk of a composite 
of nonfatal cardiovascular outcomes and all-cause mortality.14 These findings require further 
studies to comprehensively evaluate the effects of adding insulin versus oral medications and the 
efficacy of each.   
A second study by Roumie et al. evaluated the effectiveness of sulfonylurea and 
metformin monotherapy on cardiovascular outcomes in the veteran population.  Patients were 
evaluated for a composite outcome of hospitalization for acute MI, stroke, or death. This study 
showed that there was a higher rate of cardiovascular events in sulfonylurea monotherapy 
patients when compared to metformin monotherapy.  This included glyburide and glipizide in 
the sulfonylurea group.  It is important to note that this population included mostly white men.  
Data on women and minority groups was limited, although the study was representative of the 
veteran’s health population. This study concluded the use of sulfonylureas is associated with an 
increased hazard of cardiovascular events or death when compared to metformin 
monotherapy.14 It is also important to note that this study only compared the monotherapy use 




Providers should consider the practical aspects of these drugs prior to initiating therapy 
in diabetes patients.  In an effort to target patient specific concerns, factors such as cost, 
hypoglycemia risk, weight change, efficacy and range of A1c reduction, and administration 
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method should be addressed. Of the drugs compared in this paper, metformin, GLP-1 agonists, 
and sulfonylureas are all highly effective drugs in the treatment of type 2 diabetes, while DPP-4 
inhibitors are classified as intermediate.16 It is known that excessive weight and adipose tissue 
has an impact on diabetes and the progression of the disease. Metformin has been shown to be 
weight neutral, with a slight possibility of weight loss. DPP-4 inhibitors are weight neutral while 
sulfonylureas cause weight gain. GLP-1 agonists have been proven to assist in weight reduction 
among type 2 diabetes patients.  
In regard to cardiovascular disease and outcomes, DPP-4 inhibitors and sulfonylureas are 
neutral in mitigating risk. Metformin has a potential benefit for cardiovascular disease. Currently, 
one GLP-1 agonist has been FDA approved and shown to benefit cardiovascular outcomes – 
liraglutide.16 Only one class of medications discussed in this paper, DPP-4 inhibitors, pose a 
potential risk for patients with comorbid heart failure.16  
Renal effects of diabetic drugs should be carefully evaluated due to end organ damage 
caused by the pathophysiologic process of diabetes. While metformin should not be used in 
patients with eGFR <30, it does not lead to the progression of kidney disease. This is a common 
theme among diabetic medications. Liraglutide, a GLP-1 agonist, has been shown to benefit 
kidney disease in diabetic patients. Other GLP-1 agonists do require dosing adjustments for use 
in patients with kidney disease.16  
Perhaps one of the most widely used aspects in the decision-making process of add on 
therapy for diabetics is the cost of the medication. Newer drugs come at higher costs that are 
typically not initially covered by insurance providers. Both GLP-1 agonists and DPP-4 inhibitors 
are high cost medications, while metformin and sulfonylureas are much cheaper, increasing 
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compliance with patients. It is also important to discuss with patients their desire to avoid or to 
use injectable therapies. Of the drugs discussed in this paper, GLP-1 agonists are injectable drugs. 
It is important to discern the level of compliance with injectable therapies a patient is likely to 
have. The proven benefits of a drug will not affect a patient if he/she is not using the drug at all 
or even using the drug correctly.16 
Other important considerations include FDA issued warnings, black box warnings, and 
common side effects which could reduce use of certain medications. Metformin has well known 
gastrointestinal side effects that some patients are often unable to tolerate. These include 
diarrhea, nausea, abdominal pain, etc. The FDA has issued a black box warning for GLP-1 agonists 
due to some studies showing an increased risk of thyroid C-cell tumors with the use of liraglutide, 
albiglutide, dulaglutide, and extended release exenatide. These drugs, along with another 
member of the incretin family, DPP-4 inhibitors, also show a potential for a higher risk of 
pancreatitis, which needs further investigation. A special warning was issued for sulfonylureas 
following studies showing an increased risk of cardiovascular mortality. It is important to note 
this was a first-generation sulfonylurea called tolbutamide, which is no longer recommended for 
use.  
CONCLUSION 
The question posed regarding cardiovascular outcomes of metformin and sulfonylureas 
versus metformin and incretin therapies still remains. Simply put, there have been a lack of 
studies directly comparing combination therapy for type 2 diabetes. With the prevalence of 
diabetes in the United States alone, it is certainly an area that warrants further investigation to 
guide the standard of care in years to come.  
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Current studies are underway directly comparing combination therapies. The results of 
the CARMELINA trial by Boehringer Ingelheim and Eli Lilly & Co. are expected soon. This trial 
evaluates the cardiovascular outcomes of linagliptin. A second trial by the same researchers is 
nearing completion and results should be released soon.  The CAROLINA trial directly compares 
linagliptin with a second-generation sulfonylurea, glimepiride. These trials should assist in 
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